1. Viral clearance

Standard Treatment (S)
Covid19 Patients Turning
Negative in days (RT-PCR)

1.61% 1 Day 0-4
37.10% 23 Day 5-11
61.29% 38 Day 12-14

Total=62

Standard+Vedicinals9 (SV9)
Covid19 Patients Turning
Negative in days (RT-PCR)

29.03% 18 Day 0-4
48.39% 30 Day 5-11
22.58% 14 Day 12-14

Total=62

Fig 1a Effect of VEDICINALS-9 on COVID-19 positive patient's turning negative in days (RT-PCR) from day 0 to 14. Data interpret following: comparison of number of patients turning negative in0-4, 5-11 and 12-14 days, when vedicinals-9 (5000mg) adjuvant with standard intervention compared with standard intervention alone. Data represented as change in expected and observed values in two comparable interventional group (n=62 per group). Significant at *P<0.05, when compared before and after intervention at 0-4, 5-11 and 12-14 daysin both interventional groups. [Chi-Square test for proportions].

The percentage of COVID-19 positive patient's (RT-PCR) turning negative in 0-4, 5-11, 12-14 days were 29.03%, 48.39% and remaining 22.58% respectively in Vedicainals-9 adjuvant group compared to the standard treatment alone group 1.61%, 37.10% and remaining 61.29% respectively. The results show more patients getting negative in first 5 days in Vedicainals-9 adjuvant group compared to standard alone group.

**Patient turning negative (RT-PCR)
cumulative in days (0-14)**

Fig 1b Cumulative no. of COVID-19 patients turning negative in days (RT-PCR)

2. CRP

C-Reactive Protein (CRP)

Fig 2 Effect of VEDICINALS-9 on serum CRP levels (mg/L) of COVID-19 positive patients from day 0 to 5, 12 and 45. Data interpret following: comparison of serum CRP levels (mg/L) from day 0 to 5, 12 and 45, when vedicinals-9 (5000mg) adjuvant with standard intervention compared with standard intervention alone. Data represented as change in serum CRP levels (Mean ± SEM) in two comparable interventional group (n=62 per group). Significant at *p<0.05, **p<0.01, ***p<0.001 when compared before and after intervention at day 5, 12 and 45 in both interventional groups. [One-way ANOVA followed by dunnett's multiple comparison test]

*The improvement (decrease) in mean serum CRP levels (mg/L) of COVID-19 positive patients from day 0 to 5, 12 and 45was significant (10.29±1.44 to 6.93±0.47, ***P<0.001), (5.04±0.32, ***P<0.001) and (3.33±0.18, ***P<0.001)in Vedicinals-9 adjuvant group compared to the standard treatment alone (12.04±0.87 to 9.23±0.49, **P<0.01), (5.15±0.32, ***P<0.001) and (3.54±0.18, ***P<0.001).*

3. Total Antibody

Total Antibody

Fig 3 Effect of VEDICINALS-9 on serum Total antibody levels of COVID-19 positive patients from day 0 to 5, 12 and 45. Data interpret following: comparison of serum Total antibody levels from day 0 to 5, 12

and 45, when vedicinals-9 (5000mg) adjuvant with standard intervention compared with standard intervention alone. Data represented as change in serum Total antibody levels (Mean ± SEM) in two comparable interventional group (n=62 per group). Significant at *p<0.05, **p<0.01, ***p<0.001, when compared before and after intervention at day 5, 12 and 45 in both interventional groups. [One-way ANOVA followed by dunnett's multiple comparison test]

*The improvement (Increase) in mean serum Total antibody levels (g/L) of COVID-19 positive patients from day 0 to 5, 12 and 45was significant (2.61±0.42 to 5.02±0.47, 5.97±0.46 and 13.64±1.44, *p<0.05, *p<0.05**p<0.01)in Vedicainals-9 adjuvant group compared to the standard treatment alone (1.92±0.37to 3.64±0.72, 3.63±0.27 and 11.23±1.15, p>0.05(ns), p>0.05(ns) and **p<0.01).*

4. IL-6

Fig 4 Effect of VEDICINALS-9 on serum IL-6 levels (pg/mL) of COVID-19 positive patients from day 0 to 5, 12 and 45. Data interpret following: comparison of serum IL-6 levels (pg/mL) from day 0 to 5, 12 and 45, when vedicinals-9 (5000mg) adjuvant with standard intervention compared with standard intervention alone. Data represented as change in serum IL-6 levels (Mean ± SEM) in two comparable interventional group (n=62 per group). Significant at *p<0.05, **p<0.01, when compared before and after intervention at day 5, 12 and 45 in both interventional groups. [One-way ANOVA followed by dunnett's multiple comparison test]

*The improvement (decrease) in mean serum IL-6 levels (pg/mL) of COVID-19 positive patients from day 0 to 5, 12 and 45 was significant (12.79±5.35 to 4.01±0.36, 3.62±0.39 and 2.70±0.24, *p<0.05, *p<0.05 **p<0.01)in Vedicainals-9 adjuvant group compared to the standard treatment alone (12.48±4.53 to 5.91±1.53, 6.18±1.83 and 2.98±0.68, p>0.05(ns), p>0.05(ns) and **p<0.01).*

5. D-Dimer

D-Dimer

Fig 5 Effect of VEDICINALS-9 on serum D-Dimer levels (µg FEU/L) of COVID-19 positive patients from day 0 to 12 and 45. Data interpret following: comparison of serum D-Dimer levels (µg FEU/L) from day 0 to day 12 and 45, when vedicinals-9 (5000mg) adjuvant with standard intervention compared with standard intervention alone. Data represented as change in serum D-Dimer levels (Mean ± SEM) in two comparable interventional group (n=62 per group). Significant at *$p<0.05$, **$p<0.01$, when compared before and after intervention at day 12 and 45 in both interventional groups. [One-way ANOVA followed by dunnett's multiple comparison test].

*The improvement (decrease) in mean serum D-Dimer levels (µg FEU/L) of COVID-19 positive patients from day 0 to 12 and 45 was significant (416.7±43.45 to 351.8±28.48 and 261.5±14.15, $p>0.05$ (ns) and ***$p<0.001$) in Vedicainals-9 adjuvant group compared to the standard treatment alone (410.8±45.67 to 687.7±187.2 and 285.4±12.34, $p>0.05$ (ns) and $p>0.05$ (ns).*

6. X-Ray

X-Ray

Fig 6 X-Ray findings of COVID-19 positive patients from day 0 to 45. Data interpret following: Percentage of COVID-19 positive patients from day 0 to day 45, when vedicinals9 5000mg adjuvant with

standard intervention compared with standard intervention alone. Data represented as percentage of patients with abnormal findings of X-ray in two comparable interventional group (n=62 per group).

Before the start of the treatment at day 0, 37.10% (23/62) of cases had abnormal x-ray findings in standard group and 90.32% (56/62) in vedicinals-9 adjuvant group. After 12 ± 2 days of treatment, only 22.95% (14/61) of cases had abnormal findings in vedicinals-9 adjuvant group resulting in 77.05% (47/61) of cases with normal findings compared to standard group alone which showed no change at all from day 0.